{
    "root": "30a08ed5-fd52-ba49-e063-6394a90a77bc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pregabalin",
    "value": "20250318",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M"
        }
    ],
    "indications": "pregabalin capsules indicated : management neuropathic pain associated diabetic peripheral neuropathy management postherpetic neuralgia adjunctive therapy treatment partial-onset seizures patients 1 month age older management fibromyalgia management neuropathic pain associated spinal cord injury",
    "contraindications": "adult , begin dosing 150 mg/day . partial-onset seizure dosing pediatric patients 1 month age older , refer section 2.4 . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) dosing recommendations : indication sing r egi en x u dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric adult patients weighing 30 kg ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric patients weighing less 30 kg ( 2.4 ) 1 month less 4 years : 3 divided doses per day 4 years older : 2 3 divided doses per day 14 mg/kg/day . fibromyalgia ( 2.5 ) 2 di v ided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day . neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . dose adjusted adult patients reduced renal function . ( 2.7 )",
    "warningsAndPrecautions": "pregabalin capsules , 50 mg supplied white , hard gelatin capsule printed black ink “ ” cap & “ 1311 ” body . available follows : ndc : 70518-2571-00 ndc : 70518-2571-01 packaging : 90 1 bottle plastic packaging : 60 1 bottle plastic storage handling store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense tight container defined usp child-resistant closure . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "pregabalin capsules contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.2 ) ] .",
    "indications_original": "Pregabalin capsules are indicated for:\n                  \n                     Management of neuropathic pain associated with diabetic peripheral neuropathy\n                     Management of postherpetic neuralgia\n                     Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older\n                     Management of fibromyalgia\n                     Management of neuropathic pain associated with spinal cord injury",
    "contraindications_original": "For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION D o sing R egi m en M a x i m u m Dose DPN Pain (2.2) 3 divided doses per day 300 mg/day within 1 week PHN (2.3) 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More (2.4) 2 or 3 divided doses per day Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric Patients Weighing Less than 30 kg (2.4) 1 month to less than 4 years: 3 divided doses per day 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day. Fibromyalgia (2.5) 2 di v ided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day. Neuropathic Pain Associated with Spinal Cord Injury (2.6) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Dose should be adjusted in adult patients with reduced renal function. (2.7)",
    "warningsAndPrecautions_original": "Pregabalin capsules, 50 mg are supplied as white, hard gelatin capsule printed with black ink “AN” on cap & “1311” on body. They are available as follows:\n                  \n                  \n                  NDC: 70518-2571-00\n                  NDC: 70518-2571-01\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  \n                  \n                  Storage and Handling\n                  Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP with child-resistant closure.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Pregabalin capsules are contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy\n \n  [see\n  \n   Warnings and Precautions (5.2)]."
}